Skip to Main Content
DownloadHi-Res Photo

Harriet Kluger, MD

Professor of Medicine (Medical Oncology); Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Director, Yale Immuno-Oncology Training Program; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology

Contact Information

Harriet Kluger, MD

Mailing Address

  • Medical Oncology

    PO Box 208032

    New Haven, CT, 06520-8028

    United States

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Kluger is a medical oncologist and the Associate Director for Education, Training and Faculty Development at Yale Cancer Center, and the Deputy Section Chief for Medical Oncology. She sees patients with melanoma and renal cell carcinoma. Approximately half of her time is spent conducting laboratory-based clinical and translational research. She runs an active laboratory focusing on melanoma-related studies, and has been an integral member of the Yale SPORE in Skin Cancer since it was initially awarded in 2006, having co-led four projects during this time. She is currently a Director of the SPORE in Skin Cancer with Dr. Bosenberg. Dr. Kluger collaborates with basic and clinical scientists to develop new approaches for the diseases she treats, including new approaches for patients with brain metastases. Her particular focus is on predictive biomarkers and development of novel therapies, primarily immune activating approaches. She has extensive experience in conducting correlative predictive and prognostic biomarker studies using a variety of technologies, including exome sequencing, expression arrays, tissue microarrays, single cell technologies and others. Her lab conducts pre-clinical targeted drug testing and knock-down studies. She also has experience in designing and conducting clinical trials with laboratory correlates, including investigator initiated trials. All of these trials involve specimen collection (tumor and blood) and analysis. She has been very involved in development of single drug and combination checkpoint regimens, and is well versed with aspects of biomarker development for predicting response to this class of drugs.

Coauthors

Research Interests

Medical Oncology; Melanoma

Selected Publications